These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 22827748)
1. Advances in targeted therapeutic agents. Nicolaides NC; Sass PM; Grasso L Expert Opin Drug Discov; 2010 Nov; 5(11):1123-40. PubMed ID: 22827748 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
4. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Bianchini D; Zivi A; Sandhu S; de Bono JS Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208 [TBL] [Abstract][Full Text] [Related]
5. Novel therapies for malignant gliomas: a local affair? Rainov NG; Söling A; Heidecke V Neurosurg Focus; 2006 Apr; 20(4):E9. PubMed ID: 16709040 [TBL] [Abstract][Full Text] [Related]
6. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
7. Antibody conjugates and therapeutic strategies. McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252 [TBL] [Abstract][Full Text] [Related]
8. Clinically validated approaches to the treatment of autoimmune diseases. Carter PH; Zhao Q Expert Opin Investig Drugs; 2010 Feb; 19(2):195-213. PubMed ID: 20050823 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Golay J; Introna M Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378 [TBL] [Abstract][Full Text] [Related]
10. Safety profile of new anticancer drugs. Mansi L; Thiery-Vuillemin A; Nguyen T; Bazan F; Calcagno F; Rocquain J; Demarchi M; Villanueva C; Maurina T; Pivot X Expert Opin Drug Saf; 2010 Mar; 9(2):301-17. PubMed ID: 20175699 [TBL] [Abstract][Full Text] [Related]
12. Integrin targeted drug and gene delivery. Wang Z; Chui WK; Ho PC Expert Opin Drug Deliv; 2010 Feb; 7(2):159-71. PubMed ID: 20095940 [TBL] [Abstract][Full Text] [Related]
17. Drug development for cancer chemoprevention: focus on molecular targets. Johnson KA; Brown PH Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505 [TBL] [Abstract][Full Text] [Related]
19. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Wagner E; Kircheis R; Walker GF Biomed Pharmacother; 2004 Apr; 58(3):152-61. PubMed ID: 15082337 [TBL] [Abstract][Full Text] [Related]
20. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Ogris M; Wagner E Hum Gene Ther; 2011 Jul; 22(7):799-807. PubMed ID: 21563983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]